Nano cap PAVmed (PAVM +17.8%) is up on triple normal volume. Shares have jumped 60% in less than a month after it announced the availability of its EsoGuard Esophageal DNA Test (offered as a service at an Irvine, CA lab). The test is designed to aid in the diagnosis of Barrett’s esophagus (complication of gastroesophageal reflux disease) and related precursors to esophageal adenocarcinoma.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.